Remarkably, therapeutic melanoma trials with checkpoint inhibitors directed to CTLA-4 or PD-1 that prospectively stratify patients for age to assess for differences in outcome report that the response is independent of age [20–23]. Here, PDCD1 is linked to melanoma.